Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

Rhea-AI Summary

Puma Biotechnology announced the release of abstracts on its drug alisertib, which will be presented at the 2024 ASCO Annual Meeting. The event, scheduled from May 31 to June 4 in Chicago and online, will feature two key studies involving alisertib. The first, Abstract 1037, is a phase II study on alisertib in treating endocrine-resistant metastatic breast cancer, with findings presented by Dr. Karthik Giridhar from Mayo Clinic. The second, Abstract 8572, explores a phase I/Ib study of alisertib combined with osimertinib for osimertinib-resistant EGFR-mutated lung cancer, presented by Dr. Turja Chakrabarti from the University of California, San Francisco. Full abstracts are available online.

Positive

• Puma Biotechnology's participation in the prestigious ASCO Annual Meeting enhances its visibility within the scientific community.
• Presenting phase II study results on alisertib for metastatic breast cancer may highlight the drug's potential efficacy.
• Phase I/Ib study combining alisertib with osimertinib for resistant lung cancer could show promising synergy in treatment.
• Involvement of reputable institutions like Mayo Clinic and University of California can boost the credibility of the studies.

Negative

• The announcements focus on early-stage trials (Phase I/Ib and Phase II), indicating that alisertib may still be several years away from potential market approval.
• No specific data or outcomes from the studies are provided in the PR, leaving investors uncertain about the drug's performance.
• Potential financial risks due to the ongoing costs of clinical trials without guaranteed success.

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-June 4.

Full abstracts of the following posters are available online at https://conferences.asco.org/am/abstracts.

• Abstract 1037: Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC 041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)
  Presenter: Karthik Giridhar, MD., Mayo Clinic

• Abstract 8572: Phase I/Ib study of the aurora kinase A Inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer
  Presenter: Turja Chakrabarti, MD., University of California, San Francisco

About Puma Biotechnology:

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti- HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA-Lung 1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523137578/en/

Puma Biotechnology, Inc.

Alan H. Auerbach or Mariann Ohanesian, +1 424-248-6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

Russo Partners

David Schull or Olipriya Das, +1 212-845-4200

david.schull@russopartnersllc.com

olipriya.das@russopartnersllc.com

Source: Puma Biotechnology, Inc.

FAQ

What is Puma Biotechnology's stock symbol?

Puma Biotechnology's stock symbol is PBYI.

When and where is the 2024 ASCO Annual Meeting?

The 2024 ASCO Annual Meeting will be held from May 31 to June 4 in Chicago and online.

What are the key studies involving alisertib presented by Puma Biotechnology at ASCO 2024?

The key studies are a phase II study on endocrine-resistant metastatic breast cancer and a phase I/Ib study on osimertinib-resistant EGFR-mutated lung cancer.

Who are the presenters of Puma Biotechnology's alisertib studies at ASCO 2024?

Dr. Karthik Giridhar from Mayo Clinic and Dr. Turja Chakrabarti from the University of California, San Francisco.

Where can I find the full abstracts of Puma Biotechnology's studies for ASCO 2024?

Full abstracts are available online at https://conferences.asco.org/am/abstracts.